ARTICLE | Cover Story

Combining antibodies to eliminate NHL

September 23, 2010 7:00 AM UTC

A Stanford University School of Medicine team has found a way to boost the efficacy of blockbuster non-Hodgkin's lymphoma drug Rituxan rituximab

by combining the anti-CD20 antibody with mAbs against CD47.1 The group thinks the combination could elicit fewer side effects than Rituxan plus chemotherapy, which is standard care for the blood cancer...